[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603173":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":57,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":24,"enrollmentInfo":70,"targetDuration":24,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients who enroll in the RENEW intervention","Patients who agree to actively participate in the RENEW intervention designed to identify opportunities to have the beta lactam allergy label removed from their electronic medical record.",[12],"Diagnostic Test: RENEW-IN Algorithm for assessment of a beta-lactam intervention",{"label":14,"type":6,"description":15,"interventionNames":16},"Patients hospitalized with a hematologic malignancy in the time period prior to the intervention","Patients who are hospitalized with a hematologic malignancy who would meet the inclusion criteria for the intervention but who were not approached since they were hospitalized in the time period prior to introduction of the intervention. These patients will be used as a control group. Charts for these patients will be retrospectively reviewed and data will be extracted for analysis of the primary and secondary outcomes.",[17],"Other: EMR Review",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","RENEW-IN Algorithm for assessment of a beta-lactam intervention","The RENEW-IN intervention includes a detailed assessment of the participant's beta-lactam allergy history and determination of a risk-level for allergy-delabeling.",[9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"EMR Review","Electronic medical record review for comparative analysis",[14],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Ebbing Lautenbach, MD,MPH,MSCE","CONTACT","215-898-6977","ebbing@pennmedicine.upenn.edu",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hospital of the University of Pennsylvania","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-75.16362,39.95238,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":24,"phoneExt":24,"email":24},"Ebbing Lautenbach, MD, MPH, MSCE",{"type":54,"investigatorFullName":52,"investigatorTitle":55,"investigatorAffiliation":56,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Professor of Medicine and Epidemiology","University of Pennsylvania",[58],{"name":59,"class":6},"University of Utah","100603173","phase-4-allergy-delabeling-in-antibiotic-stewardship---intervention-100603173",false,"NCT07133074","Allergy Delabeling in Antibiotic Stewardship - Intervention","Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention","RENEW-IN","Inclusion Criteria:\n\n* all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service\n* reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and\u002For carbapenem)\n\nExclusion Criteria:\n\n* patients with a history of severe cutaneous adverse reaction\n* patients with a history of Stevens-Johnson syndrome\n* patients with a history of toxic epidermal necrolysis\n* patients with a history of drug-induced exfoliative dermatitis\n* patients with a history of drug reaction with eosinophilia and systemic symptoms\n* patients with a history of acute generalized exanthematous pustulosis","ALL","18 Years",{"count":71,"type":72},3800,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.",[78,79],"Beta Lactam Allergy","Hematologic Malignancy",[81,82,83],"penicillin allergy","hematologic cancer","allergy delabeling","2026-06-15",{"date":86,"type":87},"2026-06-17","ACTUAL",{"date":89,"type":87},"2026-04-20",{"date":91,"type":72},"2029-11",{"name":5,"class":6},1]